## VPA10774/001/001

## Enrox Flavour 15 mg Tablets for dogs and cats

Variation	Summary	Date
Vet - B47 d)	VNRA - Vet - B47 d) - d) To reflect compliance with the Ph. Eur. by removing reference to the internal test method and test method number - B47d) Changes to the quality part of the dossier: Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State: — to reflect compliance with the Ph. Eur. by removing reference to the internal test method and test method number	09/06/25
Vet - B44	VNRA - Vet - B44 - Submission of a new or updated Ph. Eur. CEP from an already approved manufacturer for a non-sterile active substance, starting material, reagent or intermediate, excipient - B44 Changes to the quality part of the dossier: Submission of a new or updated Ph. Eur. CEP from an already approved manufacturer for a non-sterile: — active substance; — starting material, reagent or intermediate used in the manufacturing process of the active substance; — excipient	09/06/25
Vet - B3 a)	VNRA - Vet - B3 a) - a) Deletion of a manufacturing site for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material for an active substance, reagent or excipient (when mentioned in the dossier) - B3 a) Changes to the quality part of the dossier: Deletion of a manufacturing site for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material for an active substance, reagent or excipient (when mentioned in the dossier)	25/04/25
Vet - G.I.18	VRA-S - Vet - G.I.18 - One-off alignment of the product information with version 9.0 (or the latest version of the QRD templates that are in effect at the time that this one-off variation is submitted) of the QRD templates i.e. major update of the QRD templates in accordance with Regulation (EU) 2019/6, for veterinary medicinal products placed on the market in accordance with Directive 2001/82/EC or Regulation (EC) No 726/2004 - G.I.18 Safety, Efficacy, Pharmacovigilance changes - One-off alignment of the product information with version 9.0 (or the latest version of the QRD templates that are in effect at the time that this one-off variation is submitted) of the QRD templates i.e. major update of the QRD templates in accordance with Regulation (EU) 2019/6, for veterinary medicinal products placed on the market in accordance with Directive 2001/82/EC or Regulation (EC) No 726/2004	29/11/24
Vet - C6	VNRA - Vet - C6 - Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in the Annex to Regulation (EU) 2021/17 - C6	30/09/24

	Changes to the safety, efficacy and pharmacovigilance part of the	
	dossier: Introduction of a summary of the PSMF or changes to	
	the summary of the PSMF not already covered elsewhere in the	
	Annex to Regulation (EU) 2021/17	
Vet - G.I.15 z)	VRA-R - Vet - G.I.15 z) - z) Other changes under this code level	
	e.g. variations outlined in section 6 and 7 of	20/06/24
	EMA/CMDv/7381/2021 - G.I.15 z) Safety, Efficacy,	
	Pharmacovigilance changes - Changes to the labelling or the	
	package leaflet which are not connected with the summary of	
	product characteristics - Other changes under this code level, e.g.	
	variations outlined in section 6 and 7 of EMA/CMDv/7381/2021	
Vet - F.II.b.3 a)	VRA-R - Vet - F.II.b.3 a) - a) Minor change in the manufacturing	05/09/22
	process - F.II.b.3 a) Quality Changes - Finished Product	
	-Manufacture - Change in the manufacturing process of the	
	finished product, including an intermediate used in the	
	manufacture of the finished product - Minor change in the	
	manufacturing process	
A.7	IA - A.7 - A.7 Deletion of manufacturing sites for an active	
	substance, intermediate or finished product, packaging site,	02/03/22
	manufacturer responsible for batch release, site where batch	
	control takes place, or supplier of a starting material, reagent or	
	excipient (when mentioned in the dossier)* - A.7 -	
	ADMINISTRATIVE CHANGES - Deletion of manufacturing	
	sites for an active substance, intermediate or finished product,	
	packaging site, manufacturer responsible for batch release, site	
	where batch control takes place, or supplier of a starting material,	
	reagent or excipient (when mentioned in the dossier)*	